Crescent Biopharma
Crescent Biopharma reported revenue of $11 million in fiscal 2025. Its operating margin was −1,407.5%. Free cash flow was −$72 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Crescent Biopharma does
Crescent Biopharma is a clinical-stage cancer drug company, so it has no approved products. It was formerly GlycoMimetics and took its current form in a June 2025 merger with a private company, also named Crescent Biopharma. It moved its legal home to the Cayman Islands in the same transaction.
It has two strategies. One is CR-001, an antibody designed to bind two targets at once, PD-1 and VEGF, which it hopes could take the place of Merck's Keytruda as a base cancer treatment. The other is a group of antibody drug conjugates, which carry a cancer-killing drug straight to tumor cells. These include CR-002 and CR-003. It plans to combine them in treatment.
It started a global Phase 1/2 trial of CR-001, called ASCEND, in February 2026. It expects to start trials for CR-002 and CR-003 on their own in 2026, plus the first combination trial with CR-001. It has never earned revenue from product sales.
Its biggest risks, as it describes them
- It has never had product revenue and may never be profitable.
- It needs more money, and raising it may dilute shareholders or require giving up rights.
- It depends on its lead programs CR-001, CR-002 and CR-003, which may not succeed.
- Its approach to finding and developing drugs is unproven, and others may compete in the same diseases.
Income statement
Crescent Biopharma lost money in fiscal 2025: a net loss of $154 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 90 | 48 | 42 | 35 | 213 |
| Debt incl. finance leases | — | — | — | 38 | 0 |
| Net debt (negative means net cash) | — | — | — | 3 | −213 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | 0.0x |
| Interest coverage | — | — | — | — | −69.8x |
| Current ratio | 7.7x | 5.7x | 6.4x | 3.6x | 6.6x |
| Quick ratio | 7.7x | 5.7x | 6.4x | 3.6x | 6.6x |
Cash flow
Projections
Project Crescent Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $30.6 million of Crescent Biopharma shares on the open market, and 7 insiders sold $1.5 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Joshua T BrummChief Executive Officer, Director | Sold plan | 7,837 | $16.71 | $130,956 | Form 4 |
| Sep 18, 2026 | Jonathan McNeillPresident and COO | Sold plan | 3,839 | $16.71 | $64,150 | Form 4 |
| Sep 16, 2026 | Joshua T BrummChief Executive Officer, Director | Sold plan | 1,610 | $17.90 | $28,819 | Form 4 |
| Sep 16, 2026 | Jonathan McNeillPresident and COO | Sold plan | 731 | $17.90 | $13,085 | Form 4 |
| Sep 16, 2026 | Jan PinkasChief Scientific Officer | Sold plan | 658 | $17.90 | $11,778 | Form 4 |
| Sep 16, 2026 | Ellie Eunkyung ImChief Medical Officer | Sold plan | 623 | $17.90 | $11,152 | Form 4 |
| Sep 16, 2026 | Barbara Harlin BisphamSee Remarks | Sold plan | 620 | $17.90 | $11,098 | Form 4 |
| Sep 16, 2026 | Richard William ScalzoChief Financial Officer | Sold plan | 568 | $17.90 | $10,167 | Form 4 |
| Sep 16, 2026 | Ryan LynchSee Remarks | Sold plan | 240 | $17.90 | $4,296 | Form 4 |
| Jul 16, 2026 | Fairmount Healthcare Fund II L.P.Director, 10% owner | Bought | 853,450 | $14.50 | $12.4 million | Form 4 |
| Jun 22, 2026 | Joshua T BrummChief Executive Officer, Director | Sold plan | 42,305 | $17.99 | $761,067 | Form 4 |
| Jun 22, 2026 | Jonathan McNeillPresident and COO | Sold plan | 20,549 | $17.99 | $369,677 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −349,099.6% | — | — |
| Altman Z'' | −27.47 | −4.90 | 4.59 |
| Accruals ratio | −4.2% | −16.8% | −59.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | — | — |
| F-score | — | — | — |
Compare
Put Crescent Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Crescent Biopharma | FY25 | — | −1,407.5% | −668.1% | — | — | — | |
| Zenas BioPharma | FY25 | 100.0% | −3,830.6% | −1,723.5% | — | — | — | Compare |
| Precigen | FY25 | 146.7% | −1,141.1% | −927.6% | — | — | 2 | Compare |
| Prelude Therapeutics | FY25 | 73.4% | −861.3% | −464.3% | — | — | — | Compare |
| Evommune | FY25 | 85.7% | −623.6% | −589.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | — | — | — | 10 | 1 | 0 | 0 | — | 11 |
| Revenue growth | −99.9% | — | — | — | — | −88.6% | −93.5% | −86.7% | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 23 | 24 | 40 | 47 | 45 | 48 | 28 | 20 | 14 | 138 |
| Operating income | −32 | −34 | −52 | −61 | −52 | −63 | −47 | −39 | −40 | −153 |
| Net income | −32 | −33 | −48 | −58 | −51 | −63 | −47 | −37 | −38 | −154 |
| Diluted EPS (US$) | −1.50 | −1.13 | −1.18 | −1.34 | −1.12 | −1.23 | −0.89 | −0.58 | −0.59 | — |
| Diluted shares (millions) | 21 | 29 | 41 | 43 | 46 | 52 | 52 | 63 | 64 | — |
| Cash flow | ||||||||||
| Cash from operations | −30 | −30 | −43 | −52 | −39 | −58 | −46 | −35 | −31 | −72 |
| Capital expenditure | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Free cash flow | −30 | −30 | −43 | −52 | −39 | −58 | −47 | −35 | −31 | −72 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 4 | 5 | 6 | 7 | 6 | 4 | 4 | 5 | 13 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 40 | 124 | 210 | 158 | 137 | 90 | 48 | 42 | 35 | 213 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | 38 | 0 |
| Total assets | 42 | 129 | 215 | 168 | 143 | 94 | 52 | 45 | 36 | 240 |
| Total liabilities | 7 | 9 | 9 | 14 | 15 | 13 | 9 | 7 | 47 | 37 |
| Shareholders' equity | 35 | 120 | 206 | 154 | 128 | 82 | 43 | 38 | −16 | 203 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −172,505.3% | — | — | — | −506.8% | −5,470.7% | −63,204.4% | −392,752.9% | — | −1,407.5% |
| Net margin | −171,945.1% | — | — | — | −502.1% | −5,469.0% | −62,251.7% | −368,994.2% | — | −1,419.6% |
| Free cash flow margin | −164,516.0% | — | — | — | −386.8% | −4,958.3% | −62,055.6% | −349,013.0% | — | −668.1% |
| Rule of 40 (growth + FCF margin) | −164,616.0% | — | — | — | — | −5,046.9% | −62,149.1% | −349,099.6% | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −84.0% | −42.9% | −29.7% | −32.2% | −36.1% | −60.5% | −75.0% | −90.7% | −330.3% | −164.2% |
| Return on assets | −70.0% | −38.9% | −28.1% | −30.2% | −32.8% | −53.5% | −63.9% | −76.0% | −93.6% | −111.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |